Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

This was the stock's second consecutive day of gains.

Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional ...

Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...

(RTTNews) - Assembly Biosciences, Inc. (ASMB), Thursday announced that the company has received a total of $30.1 million from Gilead Sciences, Inc. Of the total amount, $20.1 million is an equity ...

View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.